{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:11:21Z","timestamp":1789456281101,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin, Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report an atypical case of fibroblast growth factor-23 (FGF23)-mediated hypophosphatemic osteomalacia without a pathogenic variant (PV) of PHEX, who improved biochemically, clinically and radiologically post burosumab treatment. We present a narrative review of FGF23-mediated hypophosphatemic osteomalacia and propose a roadmap for investigating the etiology of hypophosphatemia to guide therapy. A 29-yr-old female with FGF23-mediated hypophosphatemic osteomalacia experienced multiple insufficiency fractures, including bilateral femoral diaphyseal fractures and delayed healing. This occurred on a background of juvenile enthesitis-related arthritis, narcolepsy, and brittle dentition since her early teens. Whole-body magnetic resonance imaging and gallium-68 DOTATATE PET scans were unremarkable, making tumor-induced osteomalacia highly unlikely. No hypophosphatemic PVs were found using massively parallel sequencing. Despite phosphate and calcitriol therapy, mild hypophosphatemia persisted with minimal improvement in fracture healing or pain. One dose of 60\u00a0mg burosumab, an anti-FGF23 antibody, led to hyperphosphatemia requiring dose titration and 3 doses of burosumab normalized renal tubular maximum reabsorption rate of phosphate relative to glomerular filtration rate. Burosumab led to fracture healing with callus formation corresponding with improved pain at fracture sites. Hypophosphatemic osteomalacia manifests with varus deformity of the lower limbs, gait disturbance, muscle weakness, enthesopathy, and dental necrosis. Evaluation of the etiology is crucial and requires an algorithmic approach to determine whether hypophosphatemia is renally-mediated, FGF23-mediated, acquired or inherited. The most common inherited cause of FGF23-mediated hypophosphatemic osteomalacia is X-linked hypophosphatemia (XLH) secondary to a PV of the PHEX gene. However, the absence of a PHEX PVs does not exclude a diagnosis of hereditary FGF23-mediated hypophosphatemic osteomalacia. Other inherited causes of this disorder include autosomal dominant and autosomal recessive hypophosphatemic rickets, fibrous dysplasia-McCune-Albright syndrome, cutaneous skeletal hypophosphatemia syndrome and osteoglophonic dysplasia. Burosumab significantly improves serum phosphate and fracture healing in XLH and may effectively treat other forms of FGF23-mediated hypophosphatemia.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziae167","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T15:29:40Z","timestamp":1734622180000},"page":"v58-v68","source":"Crossref","is-referenced-by-count":4,"title":["A case and review of fibroblast growth factor-23\u2013mediated hypophosphatemic osteomalacia in the absence of pathogenic\n                    <i>PHEX<\/i>\n                    variants"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-9306","authenticated-orcid":false,"given":"Yeung-Ae","family":"Park","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Department of Medicine, Royal Melbourne Hospital, University of Melbourne , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Department of Diabetes and Endocrinology, Monash Health , Melbourne, VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Y","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Department of Medicine, Royal Melbourne Hospital, University of Melbourne , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherie","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Department of Medicine, Royal Melbourne Hospital, University of Melbourne , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Department of Pathology, Royal Melbourne Hospital , Melbourne, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H","family":"Trainer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Royal Melbourne Hospital, University of Melbourne , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Department of Genomic Medicine, Royal Melbourne Hospital , Melbourne, VIC, 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Yates","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Department of Medicine, Royal Melbourne Hospital, University of Melbourne , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"1","key":"2025122308364830100_ref1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2025122308364830100_ref2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"issue":"11","key":"2025122308364830100_ref3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40267-018-0560-9","article-title":"Burosumab in X-linked hypophosphatemia: a profile of its use in the USA","volume":"34","author":"Lyseng-Williamson","year":"2018","journal-title":"Drugs Ther Perspect"},{"issue":"3","key":"2025122308364830100_ref4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncpneph0124","article-title":"Hypophosphatemia: an evidence-based approach to its clinical consequences and management","volume":"2","author":"Amanzadeh","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"issue":"8","key":"2025122308364830100_ref5","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1172\/jci29449","article-title":"Resurrection of vitamin D deficiency and rickets","volume":"116","author":"Holick","year":"2006","journal-title":"J Clin Invest"},{"issue":"9","key":"2025122308364830100_ref6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1301\/nr.2003.sept.320-323","article-title":"The refeeding syndrome and hypophosphatemia","volume":"61","author":"Marinella","year":"2003","journal-title":"Nutr Rev"},{"issue":"7","key":"2025122308364830100_ref7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","article-title":"Medication-induced hypophosphatemia: a review","volume":"103","author":"Liamis","year":"2010","journal-title":"QJM"},{"issue":"3","key":"2025122308364830100_ref8","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1530\/eje-12-0528","article-title":"Therapy of endocrine disease: hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature","volume":"168","author":"Witteveen","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2025122308364830100_ref9","doi-asserted-by":"publisher","first-page":"e235083","DOI":"10.1136\/bcr-2020-235083","article-title":"Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis","volume":"13","author":"Bagger","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"3","key":"2025122308364830100_ref10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/1574886311666160426141647","article-title":"Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern","volume":"11","author":"Upinder","year":"2016","journal-title":"Curr Drug Saf"},{"issue":"2","key":"2025122308364830100_ref11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00198-018-4679-2","article-title":"Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome","volume":"30","author":"Chung","year":"2019","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025122308364830100_ref12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s0002-9343(97)00275-1","article-title":"Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines","volume":"104","author":"Barak","year":"1998","journal-title":"Am J Med"},{"issue":"7","key":"2025122308364830100_ref13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/qjmed\/hcr104","article-title":"Spurious hypophosphatemia associated with monoclonal paraproteinemia","volume":"105","author":"Mao","year":"2011","journal-title":"QJM"},{"issue":"16-17","key":"2025122308364830100_ref14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.clinbiochem.2017.05.016","article-title":"Pseudohypophosphatemia associated with high-dose liposomal amphotericin B therapy","volume":"50","author":"Mays","year":"2017","journal-title":"Clin Biochem"},{"issue":"3","key":"2025122308364830100_ref15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/000456329002700312","article-title":"Pseudohypophosphataemia as a result of bilirubin interference","volume":"27","author":"Duncanson","year":"1990","journal-title":"Ann Clin Biochem"},{"issue":"7929","key":"2025122308364830100_ref16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"2","author":"Walton","year":"1975","journal-title":"Lancet"},{"issue":"3","key":"2025122308364830100_ref17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the hypophosphatemic patient","volume":"97","author":"Imel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025122308364830100_ref18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/clinem\/dgac488","article-title":"Approach to hypophosphatemic rickets","volume":"108","author":"Ackah","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025122308364830100_ref19","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/jme-20-0089","article-title":"FGF23-related hypophosphatemic rickets\/osteomalacia: diagnosis and new treatment","volume":"66","author":"Fukumoto","year":"2021","journal-title":"J Mol Endocrinol"},{"issue":"6","key":"2025122308364830100_ref20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2025122308364830100_ref21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00223-020-00692-5","article-title":"Congenital conditions of hypophosphatemia in children","volume":"108","author":"Imel","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"2025122308364830100_ref22","doi-asserted-by":"publisher","first-page":"115055","DOI":"10.1016\/j.bone.2019.115055","article-title":"Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1","volume":"129","author":"Sahoo","year":"2019","journal-title":"Bone"},{"issue":"1","key":"2025122308364830100_ref23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13256-020-02381-1","article-title":"Neurofibromatosis type 1 associated with hypophosphatemic osteomalacia due to hypersecretion of fibroblast growth factor 23: a case report","volume":"14","author":"Obo","year":"2020","journal-title":"J Med Case Rep"},{"issue":"7","key":"2025122308364830100_ref24","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.21037\/qims-22-1217","article-title":"Comprehensive imaging analysis of a patient with neurofibromatosis type 1 combined with hypophosphatemic osteomalacia: a case description","volume":"13","author":"Liu","year":"2023","journal-title":"Quant Imag Med Surg"},{"issue":"3","key":"2025122308364830100_ref25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","year":"2000","journal-title":"Nat Genet"},{"issue":"6","key":"2025122308364830100_ref26","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1210\/clinem\/dgz260","article-title":"Mutation of SGK3, a novel regulator of renal phosphate transport, causes autosomal dominant hypophosphatemic rickets","volume":"105","author":"Cebeci","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025122308364830100_ref27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.arcped.2021.03.002","article-title":"Tyrosinemia type 1 in pediatric nephrology: not always straightforward","volume":"28","author":"Brito dos Santos","year":"2021","journal-title":"Arch Pediatr"},{"key":"2025122308364830100_ref28","first-page":"27","article-title":"Hereditary tyrosinemia type I\u2014an overview","volume":"184","author":"Kvittingen","year":"1986","journal-title":"Scand J Clin Lab Invest Suppl"},{"issue":"5","key":"2025122308364830100_ref29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0248-8663(85)80031-X","article-title":"Maladie de Recklinghausen avec hypophosphor\u00e9mie et ost\u00e9omalacie: a propos de 2 observations","volume":"6","author":"Wattiaux","year":"1985","journal-title":"La Revue de M\u00e9decine Interne"},{"issue":"1","key":"2025122308364830100_ref30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jbmr.4486","article-title":"An expert perspective on phosphate dysregulation with a focus on chronic hypophosphatemia","volume":"37","author":"Aljuraibah","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025122308364830100_ref31","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025122308364830100_ref32","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/jci72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"issue":"7","key":"2025122308364830100_ref33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"21","key":"2025122308364830100_ref34","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"10189","key":"2025122308364830100_ref35","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/s0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"2025122308364830100_ref36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025122308364830100_ref37","volume-title":"Dosing and Administration Guide in Paediatric and Adult Patients: CRYSVITA\u00ae (Burosumab) Injection for Subcutaneous Use","year":"2022"},{"issue":"3","key":"2025122308364830100_ref38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of Burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2025122308364830100_ref39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jbspin.2019.07.012","article-title":"Burosumab in tumor-induced osteomalacia: a case report","volume":"87","author":"Day","year":"2020","journal-title":"Joint Bone Spine"},{"issue":"4","key":"2025122308364830100_ref40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025122308364830100_ref41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025122308364830100_ref42","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/rheumatology\/kez627","article-title":"Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia","volume":"59","author":"Amarnani","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2025122308364830100_ref43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2025122308364830100_ref44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2025122308364830100_ref45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ccr3.2595","article-title":"Recurrent severe hypophosphatemia following intravenous iron administration","volume":"8","author":"Nataatmadja","year":"2020","journal-title":"Clin Case Rep"},{"issue":"5","key":"2025122308364830100_ref46","doi-asserted-by":"publisher","first-page":"e240336","DOI":"10.1136\/bcr-2020-240336","article-title":"Rare PHEX variant with insidious presentation leads to a delayed diagnosis of X-linked hypophosphatemia","volume":"14","author":"Constantacos","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"1","key":"2025122308364830100_ref47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.6065\/apem.2020.25.1.63","article-title":"Identification of a novel variant in the PHEX gene using targeted gene panel sequencing in a 24-month-old boy with hypophosphatemic rickets","volume":"25","author":"Jo","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2025122308364830100_ref48","doi-asserted-by":"publisher","first-page":"117057","DOI":"10.1016\/j.bone.2024.117057","article-title":"Familial cases with adult-onset FGF23-related hypophosphatemic osteomalacia\u2014a PHEX 3\u2032-UTR change as a possible cause","volume":"182","author":"Sawatsubashi","year":"2024","journal-title":"Bone"},{"issue":"11","key":"2025122308364830100_ref49","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/jbmr.4702","article-title":"Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia","volume":"37","author":"Hartley","year":"2022","journal-title":"J Bone Miner Res"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae167\/61268472\/ziae167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/Supplement_5\/v58\/61268472\/ziae167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/Supplement_5\/v58\/61268472\/ziae167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:36:55Z","timestamp":1766497015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/9\/Supplement_5\/v58\/7931787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"journal-issue":{"issue":"Supplement_5","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae167","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12]]}}}